WO2014010656A1 - Agent d'accélération de la baisse de concentration d'alcool supérieur dans le sang - Google Patents

Agent d'accélération de la baisse de concentration d'alcool supérieur dans le sang Download PDF

Info

Publication number
WO2014010656A1
WO2014010656A1 PCT/JP2013/068930 JP2013068930W WO2014010656A1 WO 2014010656 A1 WO2014010656 A1 WO 2014010656A1 JP 2013068930 W JP2013068930 W JP 2013068930W WO 2014010656 A1 WO2014010656 A1 WO 2014010656A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
powder
mass
turmeric
weight
Prior art date
Application number
PCT/JP2013/068930
Other languages
English (en)
Japanese (ja)
Inventor
朋彦 中田
Original Assignee
興和株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 興和株式会社 filed Critical 興和株式会社
Priority to JP2014524858A priority Critical patent/JPWO2014010656A1/ja
Publication of WO2014010656A1 publication Critical patent/WO2014010656A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a drug that quickly improves unpleasant symptoms such as leaning, nausea and hangover after alcohol consumption.
  • piperine or herbal medicine containing piperine is known as a herbal medicine having analgesic / gastric action, blood flow increasing action, antibacterial action, etc. It is effective for use as a patent document 3), a functional gastroenteropathy therapeutic agent (patent document 4), a use as a coldness improving agent (patent document 5), and a use as a swelling improving agent (patent document 6). It has been reported. It is also disclosed that piperine is contained in a liver dysfunction inhibitor (Patent Documents 7 and 8). However, it is not known how piperine or piperine-containing crude drugs affect alcohol metabolism.
  • JP-A-8-99890 JP 2003-226650 A JP 2000-154146 A JP 2006-327999 A JP 2003-040788 A JP 2006-104109 A Japanese Patent Laid-Open No. 5-262646 JP-A-2005-112846
  • An object of the present invention is to provide a drug that quickly improves unpleasant symptoms such as leaning, nausea and hangover after alcohol consumption.
  • the present inventor has conducted intensive research, and as a result, unexpectedly using piperine or piperine-containing crude drugs promotes a reduction in blood alcohol concentration, and piperine or piperine-containing crude drugs and turmeric. It was found that when used in combination, the reduction of blood alcohol concentration was further promoted, and the present invention was completed. That is, the present invention provides a blood alcohol concentration lowering accelerator (hereinafter referred to as the blood alcohol concentration lowering accelerator of the present invention) containing piperine or a piperine-containing crude drug. The present invention also provides a blood alcohol concentration lowering accelerator containing piperine or a piperine-containing crude drug and turmeric.
  • a blood alcohol concentration lowering accelerator hereinafter referred to as the blood alcohol concentration lowering accelerator of the present invention
  • the present invention it is possible to significantly reduce the blood alcohol concentration after alcohol intake, so that after the alcohol intake, nausea, hangover and other unpleasant symptoms, more specifically, after alcohol intake, Nausea (hangover, nausea, nausea, upset stomach, nausea, nausea), vomiting, hangover, stomach / abdominal bloating, stomach hyperacidity, stomach discomfort, indigestion, heartburn, chest pain, anorexia, It is effective for improving stomach weight, stomach weakness, and stomach pain.
  • the blood alcohol concentration lowering promoter of the present invention contains at least piperine or a piperine-containing crude drug.
  • piperine is represented by the compound name (2E, 4E) -1-piperidino-5- (1,3-benzodioxol-5-yl) -2,4-pentadien-1-one, It is a compound represented by the following formula.
  • Piperine is a pungent ingredient that is widely distributed in pepper and other cognate families, such as pepper, an analgesic / healthy stomach action, blood flow increasing action, antibacterial action, antiseptic action, insecticidal action, liver function protection / improvement action, etc. It is known to have
  • piperine that is separated and purified from chemically synthesized piperine or piperine-containing crude drugs can be used, but piperine-containing crude drugs may also be used.
  • the piperine-containing herbal medicine include pepper (Pipe nigrum L.), baboon (Pipe longum L. (aka: Indiana pepper), or Piper retrofractum Vahl (aka: Javanaga pepper, Giant beetle).
  • a mature or immature fruit, pericarp, seed, fruit spike, leaf, petiole, branch, root, flower or the like is used.
  • pepper when using pepper as a piperine-containing herbal medicine, black pepper obtained by drying immature fruit of pepper, white pepper obtained by removing the peel of mature fruit and drying, or immature fruit used for black pepper Further, it is preferable to use immature green fruits, and it is more preferable to use black pepper or immature green fruits.
  • immature green fruits when using pepper as a piperine-containing herbal medicine, black pepper obtained by drying immature fruit of pepper, white pepper obtained by removing the peel of mature fruit and drying, or immature fruit used for black pepper Further, it is preferable to use immature green fruits, and it is more preferable to use black pepper or immature green fruits.
  • These can be appropriately used as a dry powder, or an extract extracted with water, lower alcohol or a mixed solvent thereof.
  • These can be used as an extract obtained by drying a powder of dried Japanese butterfly or immature fruit, or an extract extracted with water, a lower alcohol or a mixed solvent thereof.
  • Specific examples include hihatsu, hihatsu powder, hihatsu extract, hihatsu-style extract, hihatsu dried extract, hihatsu soft extract, and the like.
  • Examples of commercially available products include Hihatsu powder (manufactured by Mikuni Co., Ltd.), Hihatsu extract MF (manufactured by Maruzen Pharmaceutical Co., Ltd.), and the like.
  • the content of piperine in the blood alcohol concentration lowering promoter of the present invention is preferably 0.0001 to 5% by weight, more preferably 0.001 to 1% by weight, based on the preparation.
  • the amount of piperine used per day for adults can be generally used in the range of 0.6 g / day, preferably 0.3 g / day, but the single dose is usually in the range of 0.0001 to 0.2 g. It is preferable to make it in the range of 0.0003 to 0.1 g.
  • the content of pepper in the blood alcohol concentration lowering promoter of the present invention is preferably 0.01 to 10% by weight, and 0.1 to 5% by weight in terms of the active ingredient based on the preparation. Further preferred.
  • the amount of pepper used per day for adults can be used in a range of up to 5 g / day, preferably 3 g / day, in terms of the active ingredient, but a single dose is usually 0.01 to A range of 2 g is preferable, and a range of 0.05 to 1 g is more preferable.
  • the content of baboon in the blood alcohol concentration lowering accelerator of the present invention is preferably 0.001 to 10% by weight, and 0.01 to 5% by weight in terms of the active ingredient based on the preparation. Further preferred. If the blending amount is less than 0.01% by weight, the effect may not be sufficiently obtained. If the blending amount exceeds 5% by weight, irritation such as pungent taste becomes strong, which may be unpreferable from the viewpoint of taking feeling.
  • the daily use amount of Hihatsu per adult can be used within the range of 5 g / day, preferably 3 g / day, in terms of the active ingredient, but the single dose is usually 0.001 to The range is preferably 2 g, more preferably 0.01 to 1 g.
  • the blood alcohol concentration lowering promoter of the present invention can further contain turmeric.
  • turmeric refers to ginger family turmeric (Curcuma longa (also known as autumn turmeric) or Curcuma aromatica (also known as spring turmeric)).
  • autumn turmeric and spring turmeric can be used, but it is preferable to use autumn turmeric.
  • Turmeric used in the present invention is preferably rhizome as it is or boiled except for pericarp, and further extracted with powdered turmeric powder, water, lower alcohol or a mixed solvent thereof. What was made into the extracted extract is still more preferable. Specific examples include turmeric, turmeric powder, turmeric extract, turmeric extract, turmeric dry extract, turmeric soft extract, and fermented turmeric, and turmeric powder or turmeric extract is preferred. Examples of commercially available products include turmeric powder (manufactured by Nippon Powder Chemical Co., Ltd.), turmeric extract (manufactured by Nippon Powder Chemical Co., Ltd., Maruzen Pharmaceutical Co., Ltd.), and the like.
  • the content of turmeric when blended with the blood alcohol concentration lowering promoter of the present invention is preferably 0.01 to 60% by weight, and 0.1 to 30% by weight based on the drug substance, relative to the preparation. % Is more preferable. If the blending amount is less than 0.01% by weight, the effect may not be sufficiently obtained. If the blending amount exceeds 60% by weight, the astringency becomes strong, which may be unfavorable in terms of taking feeling.
  • the amount of turmeric used per day for an adult can be used in the range of 10 g / day, preferably 6 g / day, in terms of the active ingredient, but the single dose is usually 0.01 to 1 in terms of the active ingredient.
  • a range of 6 g is preferable, and a range of 0.1 to 2 g is more preferable.
  • the weight ratio of piperine to turmeric is preferably 1: 0.05 to 1: 60000, It is more preferably 0.5 to 1: 6000, and particularly preferably 1: 5 to 1: 600.
  • the weight ratio between the piperine-containing crude drug and turmeric is preferably 1: 0.01 to 1: 120 in terms of the drug substance. 1: 0.1 to 1:60 is more preferable, and 1: 1 to 1:10 is particularly preferable.
  • the blood alcohol concentration lowering promoter of the present invention can be taken after alcohol intake (especially the next day), before alcohol intake, or even during alcohol intake. For example, it can be taken before or during alcohol consumption to prevent an increase in blood alcohol concentration, or it can be taken the day after alcohol is consumed at night and the blood alcohol concentration increased can be reduced. In addition, so-called hangover symptoms such as leaning and nausea caused by alcohol consumption can be improved and prevented.
  • the alcohol concentration lowering promoter of the present invention can be taken in 1 to 3 doses per day depending on the degree of discomfort or the expectation of its prevention.
  • the blood alcohol concentration lowering promoter of the present invention is preferably taken orally.
  • the blood alcohol concentration lowering promoter of the present invention has an action of promoting blood alcohol concentration lowering.
  • blood alcohol concentration lowering promoting effect means the action of reducing blood alcohol concentration, reducing blood alcohol concentration increased by drinking etc. compared to the case of no treatment, And suppression / prevention of an increase in blood alcohol concentration due to drinking or the like compared to no treatment. Therefore, the blood alcohol concentration lowering promoter of the present invention can be used for the improvement and / or prevention of various symptoms caused by alcohol consumption.
  • Nausea nausea, upset stomach, nausea, nausea), vomiting, hangover, stomach and abdominal bloating, stomach hyperacidity, stomach discomfort, indigestion, heartburn, chest pain, loss of appetite, stomach weight, stomach weakness It is effective in improving and / or preventing gastric pain.
  • alcohol is synonymous with ethanol.
  • the blood alcohol concentration reduction accelerator of the present invention may be used in combination with other blood alcohol concentration reduction accelerators. Moreover, the following active ingredient and additive can be mix
  • Examples of other blood alcohol level lowering accelerators include amino acids (alanine, glutamine), rainbow trout, cordyceps, citrus molasses (derived from Wenzhou oranges), ⁇ -lactalbumin, lactulose, maltitol, lactitol, glycerol, oleanolic acid, Presenegenin, Hederagenin, Protoesigenin, Caffeine, Chixetsunin, Kyokyo, Carnitine chloride, Glycylglycine, Pepino, Kuzune, Mung bean, Red bean, Santo, Malt, Kawamata, Kashiwa, Akiko, Sandhi, Light load, Fructose, Panax ginseng , Komi-sou hot water or Kazuwa-to fermented lactic acid bacteria, guava, dry activated yeast, fructose, ascorbic acid, aroma substance, citric acid, kinin and the like.
  • amino acids alanine,
  • antacids include synthetic hydrotalcite, magnesium oxide, magnesium silicate, magnesium aluminate silicate, aluminum silicate, magnesium aluminate metasilicate, magnesium hydroxide, aluminum hydroxide, magnesium alumina hydroxide, dihydroxy Aluminum aminoacetate, sodium hydrogencarbonate, calcium carbonate, magnesium carbonate, calcium hydrogenphosphate, aminoacetic acid, funnel extract and the like can be mentioned.
  • stomachic agents include aniseed fruit, aloe, fennel, turmeric, yak, life-prolonging grass, ogon, duckweed, auren, processed bonito, gadget, cuckoo, calamus root, dry cocoon, chaff, pheasant, keihi, gentian, kojin, koboku.
  • Liver function improving agents include, for example, liver hydrolyzate, Maria Thistle, Tabana carrot, indigo, dandelion, western dandelion, burdock, garlic, chrysanthemum, western yarrow, gardenia, sesame, asparagus, onion, chicory, medicinal salvia , Korean thistle (artichoke), wolfberry, legumes / iridaceae / rose family plants (for example, soybeans and kudzu, asparasas lineneas belonging to legumes), Japanese quail, elba de pasarinho, cetesangria, red buds, tea, Saiko, peach seed, peony skin, safflower, three crests, gadgets, turmeric, ⁇ -lipoic acid, flavonols, flavones, flavans, flavanols, catechins, isoflavones, lignanic acid, curcuminoids, glutelin, prolamin, G
  • Examples of the digestive agent include starch digestive enzyme, protein digestive enzyme, fat digestive enzyme, fibrin digestive enzyme, ursodesoxycholic acid, oxycoranoates, cholic acid, bile powder, bile extract (powder), dehydrocol Acid, animal gall (including yutan) and the like.
  • intestinal adjusting agent examples include live intestinal fungi components, natto kinase, akame koji, asenyaku, aloe, ubai, ketsumeishi, genokosho, plantago obata and the like.
  • Antidiarrheal agents include, for example, acrinol, berberine chloride, guaiacol, creosote, phenyl salicylate, guaiacol carbonate, berberine tannate, bismuth hyposalicylate, bismuth nitrate, bismuth carbonate, bismuth gallate, tannic acid, albumin tannate , Methylene thymol tannin, kaolin, pectin, medicinal charcoal, calcium lactate, Acacia yam, buckwheat, duckweed, auren, kudin, ganodermone, pentaploid, hawthorn, yellowtail, ivy.
  • analgesic and antispasmodic agents include oxyphencyclimine hydrochloride, dicyclomine hydrochloride, methixene hydrochloride, scopolamine hydrobromide, methyl atropine bromide, methyl anisotropine bromide, methyl scopolamine bromide, butyl scopolamine bromide, methyl bromide- l-hyostiamine, methylbenactidium bromide, belladonna extract, belladonna total alkaloid, iodopropamide, diphenylpiperidinomethyldioxolane iodide, funnel extract, funnel root total alkaloid citrate, papaverine hydrochloride, engosac, licorice, Examples include kokuboku and peonies.
  • gastric mucosa repairing agent examples include sodium azulenesulfonate, aldioxa, glycyrrhizic acid and salts thereof, and licorice extract, L-glutamine, copper chlorophyllin potassium, copper chlorophyllin sodium, histidine hydrochloride, porcine gastric wall pepsin degradation product, porcine gastric wall acid Hydrolysates, methylmethionine sulfonium chloride, red buds, engosac, licorice, sucralfate, rebamipide, marzulene, polaprezinc, sodium alginate, gefarnate, teprenone, troxipide, benexate betadex, prunotol, irsogladine maleate, sofalcone, etc. It is done.
  • vitamins include nicotinic acid amide, calcium pantothenate, biotin, vitamin B 1 or a derivative or salt thereof, vitamin B 2 or a derivative or salt thereof, vitamin B 6 or a derivative or salt thereof, vitamin C or Derivatives or salts thereof, vitamin E or derivatives or salts thereof, and the like.
  • antifoaming agent examples include dimethylpolysiloxane.
  • Antiemetics include, for example, granisetron, domperidone, sulpiride, ondansetron, azasetron, dimenhydrinate, metoclopramide, chlorpromazine, diphenidol hydrochloride, diphenhydramine, diphenhydramine hydrochloride, meclizine, promethazine, chlorpheniramine, chlorpheniramine maleate, Examples include amphetamine, atropine, bromvalerylurea, allylisopropylacetylurea, caffeine, theophylline, mint oil, l-menthol, dl-menthol, vitamin B6 and the like.
  • Additives include physiologically excipients, binders, disintegrants, lubricants, stabilizers, thickeners, solubilizers, preservatives, pH adjusters, colorants, sweeteners, etc. There are various acceptable types.
  • excipient examples include lactose, starches, crystalline cellulose, sucrose, mannitol, light anhydrous silicic acid and the like.
  • binder examples include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan and the like.
  • disintegrant examples include carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, and low-substituted hydroxypropylcellulose.
  • Examples of the lubricant include magnesium stearate and talc.
  • the stabilizer examples include ascorbic acid, edetic acid, and salts thereof.
  • thickener examples include carmellose sodium, agar, gelatin, polyvinyl alcohol, polyvinyl pyrrolidone and the like.
  • solubilizer examples include hydrogenated oil, polyoxyethylene hydrogenated castor oil, nonionic surfactants such as sucrose fatty acid ester and glyceryl monostearate, and lecithin.
  • preservative examples include benzoic acid, sodium benzoate, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, isobutyl paraoxybenzoate and the like.
  • pH adjuster examples include citric acid, malic acid, lactic acid, tartaric acid, acetic acid, hydrochloric acid, phosphoric acid, and salts thereof, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, and the like.
  • Examples of the colorant include titanium oxide, tar pigment, yellow No. 4, yellow No. 5, ferric oxide, yellow ferric oxide, red No. 3 and the like.
  • sweetening agent examples include sucrose, liquid sugar, fructose, fructose glucose liquid sugar, reduced maltose water candy, honey, caramel, sorbitol, maltitol, xylitol, erythritol, sucralose, stevia, glycyrrhizic acid or a salt thereof, aspartame, acesulfame Potassium etc. are mentioned.
  • the blood alcohol concentration lowering accelerator of the present invention can be taken alone, or it can be contained in a pharmaceutical composition together with other active ingredients and additives, or used in the form of a food additive or food supplement. It can also be included in various foods and drinks and provided as healthy foods and drinks. Moreover, according to the objective of this invention, it can manufacture in dosage forms, such as a liquid agent, a powder, a granule, a tablet, a chewable tablet, a film-coated tablet, a sugar-coated tablet, a soft capsule, a hard capsule, and a jelly agent by a well-known and usual technique.
  • a pharmaceutical or a food or drink containing the same is marked with an indication that it is used for the improvement and / or prevention of various symptoms caused by alcohol intake Good.
  • indications such as “to prevent or alleviate nausea, stomach upset and nausea”, “prevent hangover by drinking before drinking”, “energetic next day after drinking”, etc.
  • a display can be attached to the container and packaging means by a known method, whereby the blood alcohol concentration lowering accelerator of the present invention, the pharmaceutical or food and drink containing the same are variously attributed to alcohol intake. Since it is clearly shown that it is used for symptom improvement and / or prevention, the distinction from a normal agent or food and drink becomes clear.
  • Alcohol metabolism experiment An alcohol metabolism experiment was performed according to the following experimental method. Using Wistar male rats (8-9 weeks old) fasted overnight, a single sample of the drug (10 mL / kg) was orally administered, and 1.5 hours later, an aqueous ethanol solution (500 mg / kg) was added. Similarly, it was administered orally. Blood was collected from the tip of the tail at 30, 60, 90, and 120 minutes after administration of the aqueous ethanol solution, and the ethanol concentration in the blood was measured. The blood ethanol concentration collected at each time was measured using F kit alcohol (manufactured by JK International).
  • the drug sample is a control (saline), turmeric powder (autumn turmeric) 2000 mg / kg, chickweed powder (Java turmeric) 500 mg / kg, or turmeric powder (autumn turmeric) 2000 mg / kg + chick moth powder (Chinese pepper) ) 4 groups of 500 mg / kg each dissolved or suspended in physiological saline.
  • the numerical value of each group is a crude drug dose (mg) per body weight (kg) of a rat.
  • the ethanol concentration in blood when each drug sample was administered was plotted over time, and the results are shown in FIG. Next, the AUC of blood ethanol concentration 30 to 120 minutes after ethanol administration was calculated from the results of FIG. 1, and the results are shown in FIG.
  • the average AUC ratio of blood ethanol concentration in each group was 0.699 for the turmeric powder 2000 mg / kg group, 0.289 for the chickpea powder 500 mg / kg group, and 2000 mg / kg turmeric powder when the control was 1.
  • the combination group of Hihatsu powder 500 mg / kg is 0.102.
  • the product of the AUC ratios of the turmeric powder 2000 mg / kg group and the hihatsu powder 500 mg / kg group calculated according to the Burgi method (Keijiro Takagi et al .: Pharmacology, 1987, see Nanzan-do) is 0.202, and the above combination Greater than the group value. That is, a synergistic effect in the combination group was shown. From the above, compared with turmeric, which has been conventionally known to promote alcohol metabolism, hihatsu has a higher alcohol metabolic capacity improving effect, and further increases alcohol metabolic capacity by combining hihatsu and turmeric. It was shown that an effect can be obtained.
  • the following production examples 1 to 12 show production examples of the alcohol concentration lowering accelerator of the present invention.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol.
  • the kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules). Further, 6 parts by mass of l-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol.
  • the kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules). Further, 6 parts by mass of l-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
  • ⁇ Production Example 9> Add 12 parts by mass of ethanol to the mixed powder consisting of 40 parts by mass of black pepper, 25 parts by mass of vitamin B1, 50 parts by mass of hardened oil, 20 parts by mass of glyceryl monostearate, 15 parts by mass of corn starch and 15 parts by mass of carmellose calcium. A compound was made. The kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as A granules).
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol.
  • the kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules). Further, 6 parts by mass of l-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
  • a mass part was added and the kneaded material was manufactured.
  • the kneaded product was extruded and granulated ( ⁇ 0.5 mm), dried and sized to obtain granules (hereinafter referred to as A granules).
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made.
  • the kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules). Further, 4 parts by mass of l-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made.
  • the kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules). Further, 4 parts by mass of l-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made.
  • the kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules). Further, 4 parts by mass of l-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
  • the drug of the present invention contains piperine or a piperine-containing crude drug and turmeric, unpleasant symptoms such as leaning, nausea and hangover after alcohol consumption can be quickly improved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent d'accélération de la baisse de concentration d'alcool dans le sang qui soulage rapidement divers symptômes déplaisants provoqués par une consommation d'alcool, tels que le ballonnement, la nausée et la gueule de bois. Selon l'invention, l'agent d'accélération de la baisse de concentration d'alcool dans le sang est obtenu par addition de pipérine ou d'un médicament naturel contenant de la pipérine à une préparation.
PCT/JP2013/068930 2012-07-11 2013-07-11 Agent d'accélération de la baisse de concentration d'alcool supérieur dans le sang WO2014010656A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014524858A JPWO2014010656A1 (ja) 2012-07-11 2013-07-11 優れた血中アルコール濃度低下促進剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012155745 2012-07-11
JP2012-155738 2012-07-11
JP2012155738 2012-07-11
JP2012-155745 2012-07-11

Publications (1)

Publication Number Publication Date
WO2014010656A1 true WO2014010656A1 (fr) 2014-01-16

Family

ID=49916097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/068930 WO2014010656A1 (fr) 2012-07-11 2013-07-11 Agent d'accélération de la baisse de concentration d'alcool supérieur dans le sang

Country Status (2)

Country Link
JP (1) JPWO2014010656A1 (fr)
WO (1) WO2014010656A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015077124A (ja) * 2013-09-13 2015-04-23 大正製薬株式会社 飲料
JP5801515B1 (ja) * 2014-05-08 2015-10-28 アサヒグループホールディングス株式会社 トマト含有飲食品
WO2016084290A1 (fr) * 2014-11-25 2016-06-02 アサヒグループホールディングス株式会社 Aliment ou boisson contenant un constituant dérivé d'un fruit
JP2017025056A (ja) * 2015-07-27 2017-02-02 大正製薬株式会社 ピペリン含有経口組成物
US20230248710A1 (en) * 2022-02-05 2023-08-10 Ajay Perecherla Synergistic composition for veisalgia prevention
JP7489136B2 (ja) 2020-01-27 2024-05-23 株式会社東洋新薬 肝機能改善剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05262646A (ja) * 1992-03-23 1993-10-12 Takeda Chem Ind Ltd 肝障害抑制剤
JPH0899890A (ja) * 1994-10-04 1996-04-16 Kowa Co 胃腸内服液
WO2005032569A1 (fr) * 2003-10-02 2005-04-14 Kowa Co., Ltd. Composition medicinale
JP2005112846A (ja) * 2003-09-17 2005-04-28 Lequio Pharma Co Ltd ウコン含有組成物
JP2006104109A (ja) * 2004-10-04 2006-04-20 Maruzen Pharmaceut Co Ltd むくみ感改善剤及びむくみ感改善用飲食物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100968674B1 (ko) * 2008-02-04 2010-07-06 강홍구 숙취 해소용 한약 조성물
KR101046787B1 (ko) * 2009-02-18 2011-07-05 황동철 숙취해소용 음료수 조성물
KR101176590B1 (ko) * 2010-05-26 2012-08-23 이성훈 숙취 해소용 한약 조성물 및 이를 함유하는 음료
JP2012031080A (ja) * 2010-07-29 2012-02-16 House Foods Corp 二日酔いの症状の回復剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05262646A (ja) * 1992-03-23 1993-10-12 Takeda Chem Ind Ltd 肝障害抑制剤
JPH0899890A (ja) * 1994-10-04 1996-04-16 Kowa Co 胃腸内服液
JP2005112846A (ja) * 2003-09-17 2005-04-28 Lequio Pharma Co Ltd ウコン含有組成物
WO2005032569A1 (fr) * 2003-10-02 2005-04-14 Kowa Co., Ltd. Composition medicinale
JP2006104109A (ja) * 2004-10-04 2006-04-20 Maruzen Pharmaceut Co Ltd むくみ感改善剤及びむくみ感改善用飲食物

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015077124A (ja) * 2013-09-13 2015-04-23 大正製薬株式会社 飲料
JP2020150953A (ja) * 2013-09-13 2020-09-24 大正製薬株式会社 飲料
JP5801515B1 (ja) * 2014-05-08 2015-10-28 アサヒグループホールディングス株式会社 トマト含有飲食品
WO2015170605A1 (fr) * 2014-05-08 2015-11-12 アサヒグループホールディングス株式会社 Aliment ou boisson contenant de la tomate
WO2016084290A1 (fr) * 2014-11-25 2016-06-02 アサヒグループホールディングス株式会社 Aliment ou boisson contenant un constituant dérivé d'un fruit
JPWO2016084290A1 (ja) * 2014-11-25 2017-09-07 アサヒグループホールディングス株式会社 果物由来成分含有飲食品
JP2017025056A (ja) * 2015-07-27 2017-02-02 大正製薬株式会社 ピペリン含有経口組成物
JP7489136B2 (ja) 2020-01-27 2024-05-23 株式会社東洋新薬 肝機能改善剤
US20230248710A1 (en) * 2022-02-05 2023-08-10 Ajay Perecherla Synergistic composition for veisalgia prevention

Also Published As

Publication number Publication date
JPWO2014010656A1 (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
WO2014010656A1 (fr) Agent d'accélération de la baisse de concentration d'alcool supérieur dans le sang
CN104922145B (zh) γ-氨基丁酸与壳寡糖的组合物及其制备方法和应用
US10111451B2 (en) Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor
EP2070545A1 (fr) Compositions orales pour la prévention et le traitement des troubles inflammatoires du colon
EP2303297B1 (fr) Extraits solubles dans l'eau d'artemisia dracunculus (estragon russe) utilisés pour l'amélioration du métabolisme du glucose
JP2014510736A (ja) 血糖、脂血及び体重を抑制する薬物組成物
JPWO2007043363A1 (ja) 低血糖症状抑制用組成物
WO2014010658A1 (fr) Préparation contenant du piment long indien
CN104840800B (zh) 竹叶黄酮与γ-氨基丁酸的组合物及其制备方法和应用
JP2014114253A (ja) 生薬を含有する鎮痛抗炎症用組成物
KR101910013B1 (ko) 한약재 추출물（ｓｏｃｇ）을 함유하는 통증의 개선, 예방 또는 치료용 조성물
JP4667244B2 (ja) 医薬組成物
KR20150106340A (ko) 우콘 중의 유효 성분을 함유하는 저수분계 조성물
JP4355967B2 (ja) 医薬組成物
KR101528557B1 (ko) 천년초 발효물 함유 의약 조성물
WO2017084631A1 (fr) Composition pharmaceutique et méthode destinées à prévenir ou traiter le foie gras, à améliorer les pathologies provoquées par un foie gras, le diabète sucré ou d'autres maladies associées
KR20200140103A (ko) 틱장애, 뚜렛증후군 또는 강박장애의 예방 또는 치료용 조성물
JP5823131B2 (ja) 防風通聖散含有組成物
JP6771274B2 (ja) 内服用組成物
JP6114133B2 (ja) クコシエキス含有内服液剤、可溶化剤および可溶化方法
KR102482128B1 (ko) 관절염 치료효과가 증가된 새로운 메틸설포닐메탄(msm)을 함유하는 조성물 및 그 제조방법
JP2002371001A (ja) 白内障の予防または治療剤
JP7503424B2 (ja) コエンザイムｑ１０安定化組成物、コエンザイムｑ１０を安定化するための組成物、コエンザイムｑ１０の安定化方法
JP5452042B2 (ja) 医薬組成物
JP2002212085A (ja) 尿酸値低下剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13816701

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014524858

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014/16392

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13816701

Country of ref document: EP

Kind code of ref document: A1